key: cord-0821629-jxc065co
authors: Aikawa, Tadao; Takagi, Hisato; Ishikawa, Kiyotake; Kuno, Toshiki
title: Myocardial injury characterized by elevated cardiac troponin and in‐hospital mortality of COVID‐19: an insight from a meta‐analysis
date: 2020-06-02
journal: J Med Virol
DOI: 10.1002/jmv.26108
sha: ced1e28a3735c2e8984c36fec0c1eea4a6e3d780
doc_id: 821629
cord_uid: jxc065co

Elevation of high‐sensitivity cardiac troponin (hs‐cTn) is a surrogate of myocardial injury, which appears to be a common complication of coronavirus disease 2019 (COVID‐19). In this study, a meta‐analysis was performed to clarify the association between myocardial injury assessed by hs‐cTn levels and in‐hospital mortality in patients with COVID‐19. All existing studies on myocardial injury in patients with COVID‐19 were retrieved from PubMed and EMBASE through April 13, 2020. In cases where overlap of the study population or enrollment period was found in articles published from the same hospitals, the article with the largest number of patients was only included in the analysis. The pooled odds ratio was calculated using inverse variance weighted random‐effects models. Six observational studies which included a total of 1,231 patients met the search criteria. The percentage of patients with hs‐cTn levels varied across the studies (13‐41%). Elevated hs‐cTn levels were significantly associated with an increase in in‐hospital mortality (pooled odds ratio, 22.7; 95% confidence interval, 13.6‐38.1; P<0.001) with a moderate heterogeneity (I (2)=28%), suggesting that elevated hs‐cTn levels might be used as a reliable marker of disease severity early in the course of COVID‐19. This article is protected by copyright. All rights reserved.

To the Editor:

Since December 2019, coronavirus disease 2019 (COVID-19) caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emerged as a public health emergency of international concern. As of May 22, 2020, the World Health Organization declare that approximately 5,000,000 cases of COVID-19 have been confirmed globally with more than 320,000 deaths. 1 Patients with COVID-19 show diverse clinical manifestations that range from no symptoms to severe pneumonia and even death. We are now encountering the difficulties in how to identify patients at risk for severe disease early in the course of COVID-19. A number of potential risk factors predicting poor prognosis of COVID-19 have been demonstrated, including older age, 2,3 the presence of cardiovascular disease, 2 lymphopenia, 4 elevated D-dimer levels, 3 elevated Interleukin-6 levels, 5 and high Sequential Organ Failure Assessment (SOFA) scores. 3 In recent studies, myocardial injury characterized by elevated high-sensitivity cardiac troponin (hs-cTn) levels has been reported as an independent risk factor for in-hospital mortality in patients with COVID-19. 6,7 Given the lack of a definitive marker for risk stratification of COVID-19, we performed a meta-analysis of currently available studies to clarify the association between myocardial injury assessed by hs-cTn levels and in-hospital mortality in patients with COVID-19.

A systematic search of all existing studies on myocardial injury detected by hs-cTn in patients with COVID-19 was performed in accordance with PRISMA guideline (http://www.prisma-statement.org). We searched PubMed and EMBASE through April 13, 2020 using the following search terms: ("coronavirus 2019" OR "2019-nCoV" OR "SARS-CoV-2" OR "COVID-19" OR COVID OR "2019 novel This article is protected by copyright. All rights reserved.

coronavirus") AND (troponin OR troponins OR TnI OR cTnI OR TnT OR cTnT OR CK-MB OR "creatine kinase MB" OR "cardiac biomarkers" OR "cardiac injury" OR "cardiac damage" OR "myocardial injury" OR "myocardial damage" OR "myocardial infarction" OR myocarditis OR "clinical characteristics" OR "clinical features" OR "clinical course" OR "predictors" OR "risk factors" OR outcomes). All articles were downloaded for consolidation, elimination of duplicates, and further analyses without language or time restrictions. Studies were selected based on the following criteria: 1) published in peer-reviewed journals; 2) included only patients with laboratory-confirmed COVID-19; 3) reported the in-hospital mortality and myocardial injury defined as elevated hs-cTn levels to avoid arbitrary interference from outcome definitions. In cases where overlap of the study population or enrollment period was found in articles published from the same hospitals, the article with the largest number of patients was only included in the analysis. The pooled odds ratio was calculated using inverse variance weighted random-effects models. Statistical analyses were performed using Review Manager (RevMan) version 5. 3 identified 20 studies that reported information about hs-cTn levels ( Table 1) P<0.001) with a moderate heterogeneity (I 2 =28%).

Our meta-analysis results support previous finding that the levels of hs-cTn might help identifying patients at high risk for adverse clinical events associated with COVID-19. Elevation of hs-cTn is a surrogate of myocardial injury, which appears to be a common complication of COVID-19 with incidence rates ranging from 7% to 44% ( Table 1) . Although the mechanism of myocardial injury associated with COVID-19 is not completely understood, patients with cardiovascular disease are 4 times likely to have elevated hs-cTn levels than those without. 7 Increased myocardial oxygen demand during acute infection might induce myocardial ischemia due to exacerbations of cardiovascular diseases, including coronary artery disease, atrial fibrillation, and congestive heart failure. In fact, Guo et al. has shown a positive correlation between hs-cTn and high-sensitivity C-reactive protein, 7 supporting the theory that patients with cardiovascular disease may be susceptible to myocardial injury associated with severe systemic inflammatory response to COVID-19. 11 Other proposed mechanisms include upregulation of cytokines 3, 8 that are toxic to the myocardium and abundance of angiotensin-converting enzyme 2 receptor in the heart, which is the main receptor for SARS-CoV-2 cell entry. 12 Further researches are needed to assess the continuous relationship between mortality and hs-cTn levels in

the early phase of the disease and the role of these mechanisms in patients with and without preexisting cardiovascular diseases. Larger patient data sets will allow us to adjust hs-cTn levels for other confounding factors and inflammatory biomarkers, which might be helpful to establish hs-cTn as an independent predictor of poor outcome in COVID-19.

So far, 5 meta-analyses have reported the association between myocardial injury and disease severity or mortality of COVID-19. 13 

World Health Organization. Coronavirus disease (COVID-19)

Cardiovascular disease, drug therapy, and mortality in Covid-19

Clinical course

Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study

Potential effects of coronaviruses on the cardiovascular system: a review

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): evidence from a meta-analysis. Prog Cardiovasc Dis

Cardiac injury is associated with mortality and critically ill pneumonia in COVID-19: a meta-analysis

The impact of 2019 novel coronavirus on heart injury: a systemic review and meta-analysis. Prog Cardiovasc Dis

Values are mean ± standard deviation, median (interquartile range), or n (%). hs-cTn, high-sensitivity cardiac troponin; NA, not available; URL, 99th percentile upper reference limit.